Duda Lab
Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
J Immunother Precis Oncol. 2024;7(4):255-262 - PMID: 39524465 - PMCID: PMC11541930 - DOI: 10.36401/JIPO-24-6
Morita S, Lei PJ, Shigeta K, Ando T, Kobayashi T, Kikuchi H, Matsui A, Huang P, Pittet MJ, Duda DG
Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma.
Cancer Immunol Res. 2024;:ePub - PMID: 39514263 - DOI: 10.1158/2326-6066.CIR-24-0324
Pal R, Krishnamoorthy M, Matsui A, Kang H, Morita S, Taniguchi H, Kobayashi T, Morita A, Choi HS, Duda DG, Kumar ATN
Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity.
Cancer Res. 2024;:ePub - PMID: 39514403 - DOI: 10.1158/0008-5472.CAN-24-0880
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;:1-8 - PMID: 39427654 - DOI: 10.1159/000541250
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Johnston A, Olugbami JO, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
ACS Pharmacol Transl Sci. 2024;7(10):3155-3169 - PMID: 39416967 - PMCID: PMC11475281 - DOI: 10.1021/acsptsci.4c00358
Park RJ, Parikh M, Pappas L, Sade-Feldman M, Kulkarni AS, Bi L, LaSalle TJ, Galway A, Kuhlman C, Blaszkowsky LS, Meyerhardt JA, Enzinger PC, Biller L, Allen JN, Kagey MH, Baum J, Sirard C, Duda DG, Zhu AX, Abrams TA, Hacohen N, Ting DT, Mehta A, Goyal L
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
medRxiv. 2024;:ePub - PMID: 39417106 - PMCID: PMC11483019 - DOI: 10.1101/2024.10.08.24315092
Ho AY, Shiao S, Kobald SA, Chen J, Duda DG, Ly A, Bossuyt V, Cho HL, Arnold B, Knott S, Gupta GP, McAndrew P, Karlan S, Tighiouart M, Muzikansky A, Basho R, McArthur H
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;:JCO2400003 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer Biomark. 2024;41(1):83-91 - PMID: 39269823 - PMCID: PMC11491993 - DOI: 10.3233/CBM-230431
Sivanand S, Gultekin Y, Winter PS, Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT, Crowder K, Kunchok T, Lau AN, Darnell AM, Jefferson A, Morita S, Duda DG, Aguirre AJ, Wolpin BM, Henning N, Spanoudaki V, Maiorino L, Irvine DJ, Yilmaz OH, Lewis CA, Vitkup D, Shalek AK, Vander Heiden MG
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - PMCID: PMC11450831 - DOI: 10.1038/s42255-024-01105-9
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Mol Cancer. 2024;23(1):156 - PMID: 39095771 - PMCID: PMC11295620 - DOI: 10.1186/s12943-024-02060-5
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Olugbami JO, Johnston A, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
bioRxiv. 2024;:ePub - PMID: 38585757 - PMCID: PMC10996603 - DOI: 10.1101/2024.03.27.587062
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
medRxiv. 2024;:ePub - PMID: 38559070 - PMCID: PMC10980136 - DOI: 10.1101/2024.03.14.24304306
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin SM, Matsui A, Hernandez A, Pu Z, Halvorsen S, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Sassi S, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Dror Michaelson M, Lee RJ, Duda DG
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
Pal R, K M, Matsui A, Kang H, Morita S, Taniguchi H, Kobayashi T, Morita A, Choi HS, Duda DG, Kumar ATN
In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.
Res Sq. 2023;:ePub - PMID: 37961361 - PMCID: PMC10635296 - DOI: 10.21203/rs.3.rs-3222037/v1
Morita S, Kikuchi H, Birch G, Matsui A, Morita A, Kobayashi T, Ruan Z, Huang P, Hernandez A, Coyne EM, Shin SM, Yarchoan M, Mino-Kenudson M, Romee R, Ho WJ, Duda DG
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models.
bioRxiv. 2023;:ePub - PMID: 37961529 - PMCID: PMC10634718 - DOI: 10.1101/2023.10.20.563378
Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Cancers (Basel). 2023;15(19):ePub - PMID: 37835569 - PMCID: PMC10571776 - DOI: 10.3390/cancers15194875
Franses JW, Duda DG
Scirrhous HCC: Another 'omic thread in the HCC tapestry.
Hepatology. 2023;79(4):747-748 - PMID: 37725712 - DOI: 10.1097/HEP.0000000000000609
Kashiwagi R, Funayama R, Aoki S, Matsui A, Klein S, Sato Y, Suzuki T, Murakami K, Inoue K, Iseki M, Masuda K, Mizuma M, Naito H, Duda DG, Unno M, Nakayama K
Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment.
Cancer Sci. 2023;114(11):4286-4298 - PMID: 37688308 - PMCID: PMC10637054 - DOI: 10.1111/cas.15952
Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A, Kitahara S, Necula L, Matei L, Dragu D, Neagu AI, Bleotu C, Diaconu CC, Popescu I, Duda DG
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Gastric Cancer. 2023;26(6):934-946 - PMID: 37668884 - DOI: 10.1007/s10120-023-01429-7
Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO
Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Oncology. 2023;101(11):730-737 - PMID: 37467732 - PMCID: PMC10614568 - DOI: 10.1159/000531870
McCullum L, Shin J, Xing S, Beekman C, Schuemann J, Hong T, Duda D, Mohan R, Lin S, Correa-Alfonso CM, Domal S, Withrow J, Bolch W, Paganetti H, Grassberger C
Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4D Blood Flow Simulations.
Int J Radiat Oncol Biol Phys. 2023;116(5):1226-1233 - PMID: 36739919 - PMCID: PMC10363211 - DOI: 10.1016/j.ijrobp.2023.01.054
Gkika E, Firat E, Adebahr S, Graf E, Popp I, Radicioni G, Lo SS, Nestle U, Nicolay NH, Niedermann G, Duda DG, Grosu AL
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
NPJ Precis Oncol. 2023;7(1):24 - PMID: 36864234 - PMCID: PMC9981559 - DOI: 10.1038/s41698-023-00358-z
Gupta N, Ochiai H, Hoshino Y, Klein S, Zustin J, Ramjiawan RR, Kitahara S, Maimon N, Bazou D, Chiang S, Li S, Schanne DH, Jain RK, Munn LL, Huang P, Kozin SV, Duda DG
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.
Cancers (Basel). 2023;15(4):ePub - PMID: 36831366 - PMCID: PMC9954510 - DOI: 10.3390/cancers15041021
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, Matsui A, Pu Z, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
bioRxiv. 2023;:ePub - PMID: 36747853 - PMCID: PMC9901023 - DOI: 10.1101/2023.01.26.525680
Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR, Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK
Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.
Clin Cancer Res. 2023;29(8):1605-1619 - PMID: 36749873 - PMCID: PMC10106451 - DOI: 10.1158/1078-0432.CCR-22-1630
Chamseddine I, Kim Y, De B, Naqa IE, Duda DG, Wolfgang JA, Pursley J, Wo JY, Hong TS, Paganetti H, Koay EJ, Grassberger C
Predictive Model of Liver Toxicity to Aid the Personalized Selection of Proton vs Photon Therapy in Hepatocellular Carcinoma.
Int J Radiat Oncol Biol Phys. 2023;116(5):1234-1243 - PMID: 36739920 - DOI: 10.1016/j.ijrobp.2023.01.055
Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
Gut. 2023;72(6):1196-1210 - PMID: 36596711 - DOI: 10.1136/gutjnl-2022-328428
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget. 2022;13:1314-1321 - PMID: 36473155 - PMCID: PMC9726202 - DOI: 10.18632/oncotarget.28322
Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y
Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Anticancer Res. 2022;42(11):5205-5215 - PMID: 36288859 - DOI: 10.21873/anticanres.16027
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson Junior PLS, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ
Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers.
Hepatology. 2022;77(6):1943-1957 - PMID: 36052732 - DOI: 10.1002/hep.32769
Dima SO, Dumitraşcu T, Popescu I, Duda DG
Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
Chirurgia (Bucur). 2022;117(4):407-414 - PMID: 36049097 - DOI: 10.21614/chirurgia.2772
Munoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA
Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis.
Sci Rep. 2022;12(1):14449 - PMID: 36002545 - PMCID: PMC9402568 - DOI: 10.1038/s41598-022-15948-3
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
EJHaem. 2022;3(2):434-442 - PMID: 35846042 - PMCID: PMC9175677 - DOI: 10.1002/jha2.408
Saulnier Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Clin Cancer Res. 2022;28(18):3950-3957 - PMID: 35833850 - PMCID: PMC9481695 - DOI: 10.1158/1078-0432.CCR-22-1169
Morita S, Duda DG
Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
Gut. 2022;72(4):608-610 - PMID: 35772925 - PMCID: PMC10435277 - DOI: 10.1136/gutjnl-2022-327782
Martin JD, Lanning RM, Chauhan VP, Martin MR, Mousa AS, Kamoun WS, Han HS, Lee H, Stylianopoulos T, Bawendi MG, Duda DG, Brown EB, Padera TP, Fukumura D, Jain RK
Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition.
Clin Cancer Res. 2022;28(14):3076-3090 - PMID: 35584239 - PMCID: PMC9355624 - DOI: 10.1158/1078-0432.CCR-22-0486
Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X, Fan X
VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
J Transl Med. 2022;20(1):212 - PMID: 35562734 - PMCID: PMC9102726 - DOI: 10.1186/s12967-022-03416-5
Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG
Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051
Hauth F, Roberts HJ, Hong TS, Duda DG
Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.
Int J Mol Sci. 2022;23(4):ePub - PMID: 35216045 - PMCID: PMC8879105 - DOI: 10.3390/ijms23041926
Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Nat Commun. 2022;13(1):758 - PMID: 35140208 - PMCID: PMC8828745 - DOI: 10.1038/s41467-022-28279-8
Hauth F, Ho AY, Ferrone S, Duda DG
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
JAMA Oncol. 2021;7(7):1051-1059 - PMID: 33885725 - PMCID: PMC8668197 - DOI: 10.1001/jamaoncol.2021.0168
Gkika E, Adebahr S, Brenner A, Schimek-Jasch T, Radicioni G, Exner JP, Rühle A, Spohn SKB, Popp I, Zamboglou C, Sprave T, Firat E, Niedermann G, Nicolay NH, Nestle U, Grosu AL, Duda DG
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies.
Cancers (Basel). 2021;13(22):ePub - PMID: 34830880 - PMCID: PMC8616228 - DOI: 10.3390/cancers13225725
Klein S, Duda DG
Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas.
Cancers (Basel). 2021;13(19):ePub - PMID: 34638408 - PMCID: PMC8507866 - DOI: 10.3390/cancers13194919
Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
NPJ Precis Oncol. 2021;5(1):62 - PMID: 34188163 - PMCID: PMC8242049 - DOI: 10.1038/s41698-021-00197-w
Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Possada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain, RK, Vander Heiden MG
Fatty acid synthesis is required for breast cancer brain metastasis
Nature Cancer. 2021;:ePub
Ajdari A, Xie Y, Richter C, Niyazi M, Duda DG, Hong TS, Bortfeld T
Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers.
JCO Clin Cancer Inform. 2021;5:315-325 - PMID: 33764817 - PMCID: PMC8462658 - DOI: 10.1200/CCI.20.00118
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature. 2021;592(7854):450-456 - PMID: 33762733 - PMCID: PMC8046670 - DOI: 10.1038/s41586-021-03362-0
Li W, Li S, Chen IX, Liu Y, Ramjiawan RR, Leung CH, Gerweck LE, Fukumura D, Loeffler JS, Jain RK, Duda DG, Huang P
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Radiat Oncol. 2021;16(1):48 - PMID: 33663521 - PMCID: PMC7934382 - DOI: 10.1186/s13014-021-01775-9
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Gut. 2021;71(1):185-193 - PMID: 33431577 - PMCID: PMC8666816 - DOI: 10.1136/gutjnl-2020-322493
Nayak L, Molinaro AM, Peters KB, Clarke JL, Jordan JT, de Groot JF, Nghiemphu PL, Kaley TJ, Colman H, McCluskey C, Gaffey S, Smith T, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA
Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients.
Clin Cancer Res. 2021;27(4):1048-1057 - PMID: 33199490 - PMCID: PMC8284901 - DOI: 10.1158/1078-0432.CCR-20-2500
Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.
Neurooncol Adv. 2020;2(1):vdaa157 - PMID: 33392506 - PMCID: PMC7764510 - DOI: 10.1093/noajnl/vdaa157
Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG
Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Clin Cancer Res. 2020;26(23):6158-6167 - PMID: 32878766 - DOI: 10.1158/1078-0432.CCR-20-1310
Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33234602 - PMCID: PMC7689089 - DOI: 10.1136/jitc-2020-001435
Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.
Oncology. 2020;98(12):836-846 - PMID: 33027788 - PMCID: PMC7704605 - DOI: 10.1159/000502482
Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, Duda DG, Roberts LR, Russell SJ, Peng KW, Borad MJ
Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers.
Mol Ther Oncolytics. 2020;18:546-555 - PMID: 32839735 - PMCID: PMC7437509 - DOI: 10.1016/j.omto.2020.08.007
Martin JD, Duda DG, Jain RK
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?
Circ Res. 2020;127(6):724-726 - PMID: 32853096 - PMCID: PMC7462096 - DOI: 10.1161/CIRCRESAHA.120.317720
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG
Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Hepatology. 2020;71(4):1247-1261 - PMID: 31378984 - PMCID: PMC7000304 - DOI: 10.1002/hep.30889
Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I
Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients.
Cancers (Basel). 2020;12(5):ePub - PMID: 32443546 - PMCID: PMC7281651 - DOI: 10.3390/cancers12051275
Kongpetch S, Jusakul A, Lim JQ, Ng CCY, Chan JY, Rajasegaran V, Lim TH, Lim KH, Choo SP, Dima S, Popescu I, Duda DG, Kukongviriyapan V, Khuntikeo N, Pairojkul C, Rozen SG, Tan P, Teh BT
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
JCO Glob Oncol. 2020;6:628-638 - PMID: 32315234 - PMCID: PMC7193781 - DOI: 10.1200/GO.20.00030
Chen J, Duda DG
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - PMCID: PMC6997488 - DOI: 10.1016/j.ebiom.2020.102644
Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res. 2020;26(1):206-212 - PMID: 31558474 - PMCID: PMC7139851 - DOI: 10.1158/1078-0432.CCR-19-1739
Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565
Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
J Clin Oncol. 2019;37(35):3446-3454 - PMID: 31626572 - PMCID: PMC7098833 - DOI: 10.1200/JCO.19.01367
Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Cancer Med. 2019;8(13):5988-5994 - PMID: 31444999 - PMCID: PMC6792497 - DOI: 10.1002/cam4.2505
Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, Duda DG, Guimaraes AR, Hong TS, Bortfeld TR, Seco J
Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy.
Clin Transl Radiat Oncol. 2019;18:113-119 - PMID: 31341986 - PMCID: PMC6630151 - DOI: 10.1016/j.ctro.2019.04.013
Saftoiu A, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, Duda DG, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol.
Endosc Ultrasound. 2019;8(4):235-240 - PMID: 31249159 - PMCID: PMC6714481 - DOI: 10.4103/eus.eus_16_19
Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep. 2019;9(1):8721 - PMID: 31197238 - PMCID: PMC6565804 - DOI: 10.1038/s41598-019-44365-2
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019;5(7):1020-1027 - PMID: 31145418 - PMCID: PMC6547247 - DOI: 10.1001/jamaoncol.2019.0892
Amoozgar Z, Jain RK, Duda DG
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749
Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer. 2019;125(13):2213-2221 - PMID: 30913304 - PMCID: PMC6763367 - DOI: 10.1002/cncr.32029
Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK
Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
NPJ Breast Cancer. 2019;5:4 - PMID: 30675514 - PMCID: PMC6333771 - DOI: 10.1038/s41523-018-0100-8
Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol. 2018;2:22 - PMID: 30374460 - PMCID: PMC6194077 - DOI: 10.1038/s41698-018-0065-y
Lee EQ, Duda DG, Muzikansky A, Gerstner E, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey SC, Batchelor T, Jain RK, Wen PY
Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
Clin Cancer Res. 2018;24(19):4643-4649 - PMID: 29941486 - DOI: 10.1158/1078-0432.CCR-18-1025
Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
Int J Radiat Oncol Biol Phys. 2018;101(5):1222-1225 - PMID: 29859792 - PMCID: PMC6050125 - DOI: 10.1016/j.ijrobp.2018.04.026
Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Sci Transl Med. 2018;10(432):ePub - PMID: 29540614 - PMCID: PMC5936748 - DOI: 10.1126/scitranslmed.aag0945
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol. 2018;15(5):325-340 - PMID: 29508855 - PMCID: PMC5921900 - DOI: 10.1038/nrclinonc.2018.29
Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics. 2018;8(4):894-905 - PMID: 29463989 - PMCID: PMC5817100 - DOI: 10.7150/thno.21168
Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
NPJ Precis Oncol. 2017;1:ePub - PMID: 29202103 - PMCID: PMC5708878 - DOI: 10.1038/s41698-017-0020-3
Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Oncolytic Virother. 2017;6:39-49 - PMID: 29184854 - PMCID: PMC5687448 - DOI: 10.2147/OV.S145262
Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J. 2017;5(7):987-996 - PMID: 29163965 - PMCID: PMC5676550 - DOI: 10.1177/2050640617695698
Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov L, Gordan R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017;7(10):1116-1135 - PMID: 28667006 - PMCID: PMC5628134 - DOI: 10.1158/2159-8290.CD-17-0368
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Sci Transl Med. 2017;9(391):ePub - PMID: 28539475 - PMCID: PMC5917603 - DOI: 10.1126/scitranslmed.aal4682
David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z. Alexander Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Yongchul Song, Carlotta Costa, Kamila Naxerova, Christina S. F. Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, C. Ryan Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Monica V. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Science Translational Medicine. 2017;9(391):eaal4682
Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
Onco Targets Ther. 2017;10:1403-1412 - PMID: 28424556 - PMCID: PMC5344425 - DOI: 10.2147/OTT.S111681
Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.
Am J Cancer Res. 2017;7(3):484-502 - PMID: 28401006 - PMCID: PMC5385638
Ramjiawan RR, Griffioen AW, Duda DG
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis. 2017;20(2):185-204 - PMID: 28361267 - PMCID: PMC5439974 - DOI: 10.1007/s10456-017-9552-y
Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Sci Rep. 2017;7:44123 - PMID: 28276530 - PMCID: PMC5343435 - DOI: 10.1038/srep44123
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Cancer. 2017;123(11):1979-1988 - PMID: 28192597 - PMCID: PMC5444988 - DOI: 10.1002/cncr.30571
Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.
Ecancermedicalscience. 2016;10:689 - PMID: 27994645 - PMCID: PMC5130328 - DOI: 10.3332/ecancer.2016.689
Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK
Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27908927 - PMCID: PMC5131752 - DOI: 10.1101/cshperspect.a031195
Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK, Fukumura D
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Sci Transl Med. 2016;8(360):360ra135 - PMID: 27733559 - PMCID: PMC5457741 - DOI: 10.1126/scitranslmed.aaf5219
Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27663981 - PMCID: PMC5131751 - DOI: 10.1101/cshperspect.a027094
Popp I, Grosu AL, Niedermann G, Duda DG
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
Radiother Oncol. 2016;120(2):185-94 - PMID: 27495145 - DOI: 10.1016/j.radonc.2016.07.013
Chng KR, Chan SH, Ng AH, Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DM, Lim KH, Soetinko R, Ong CK, Duda DG, Dima S, Popescu I, Wongkham C, Feng Z, Yeoh KG, Teh BT, Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Ngeow J, Nagarajan N
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.
EBioMedicine. 2016;8:195-202 - PMID: 27428430 - PMCID: PMC4919562 - DOI: 10.1016/j.ebiom.2016.04.034
Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113
Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY
A protein and mRNA expression-based classification of gastric cancer.
Mod Pathol. 2016;29(7):772-84 - PMID: 27032689 - DOI: 10.1038/modpathol.2016.55
Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
J Clin Oncol. 2016;34(14):1669-75 - PMID: 26976425 - PMCID: PMC4872317 - DOI: 10.1200/JCO.2015.64.3817
Hato T, Zhu AX, Duda DG
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313 - PMID: 26865127 - PMCID: PMC5619018 - DOI: 10.2217/imt.15.126
Hayano K, Kulkarni NM, Duda DG, Heist RS, Sahani DV
Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy.
AJR Am J Roentgenol. 2016;206(5):987-93 - PMID: 26934729 - DOI: 10.2214/AJR.15.15528
Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam T, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel JA, Krop I, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D
PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity.
Clin Cancer Res. 2016;22(12):2993-3004 - PMID: 26861455 - PMCID: PMC4911258 - DOI: 10.1158/1078-0432.CCR-15-1839
Botezatu A, Bleotu C, Nastase A, Anton G, Bacalbasa N, Duda D, Dima SO, Popescu I
Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
Cancer Genomics Proteomics. 2015;12(1):21-30 - PMID: 25560641
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Clin Cancer Res. 2015;21(16):3610-8 - PMID: 25910950 - PMCID: PMC4790106 - DOI: 10.1158/1078-0432.CCR-14-3220
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Hepatology. 2015;61(5):1591-602 - PMID: 25529917 - PMCID: PMC4406806 - DOI: 10.1002/hep.27665
Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Proc Natl Acad Sci U S A. 2015;112(46):14325-14330 - PMID: 26578779 - PMCID: PMC4655544 - DOI: 10.1073/pnas.1518808112
Chen Y, Duda DG
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
Oncoimmunology. 2015;4(10):e1029703 - PMID: 26451297 - PMCID: PMC4589048 - DOI: 10.1080/2162402X.2015.1029703
Samuel R, Duda DG, Fukumura D, Jain RK
Vascular diseases await translation of blood vessels engineered from stem cells.
Sci Transl Med. 2015;7(309):309rv6 - PMID: 26468328 - PMCID: PMC4799660 - DOI: 10.1126/scitranslmed.aaa1805
Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY
Familial Gastric Cancers.
Oncologist. 2015;20(12):1365-1377 - PMID: 26424758 - PMCID: PMC4679084 - DOI: 10.1634/theoncologist.2015-0205
Jain RK, Fukumura D, Duda DG
From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey.
Cancer J. 2015;21(4):235-236 - PMID: 26222072 - PMCID: PMC4791947 - DOI: 10.1097/PPO.0000000000000136
Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Nat Protoc. 2015;10(8):1264-1274 - PMID: 26203823 - PMCID: PMC4800979 - DOI: 10.1038/nprot.2015.080
Goyal L, Chong DQ, Duda DG, Zhu AX
Chemotherapy and antiangiogenics in biliary tract cancer.
Lancet Oncol. 2015;16(8):882-3 - PMID: 26179202 - DOI: 10.1016/S1470-2045(15)00093-5
Lemon CM, Karnas E, Han X, Bruns OT, Kempa TJ, Fukumura D, Bawendi MG, Jain RK, Duda DG, Nocera DG
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors.
J Am Chem Soc. 2015;137(31):9832-42 - PMID: 26149349 - PMCID: PMC4750386 - DOI: 10.1021/jacs.5b04765
Duda DG, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.
Proc Natl Acad Sci U S A. 2015;112(27):E3454 - PMID: 26080434 - PMCID: PMC4500270 - DOI: 10.1073/pnas.1507225112
Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
J Natl Cancer Inst. 2015;107(9):ePub - PMID: 26063793 - PMCID: PMC4651102 - DOI: 10.1093/jnci/djv155
Jain RK, Fukumura D, Duda DG
Lessons From 30 Years of Teaching About the Microenvironment of Tumors.
Cancer J. 2015;21(3):137 - PMID: 26049690 - PMCID: PMC4792516 - DOI: 10.1097/PPO.0000000000000119
Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Neuro Oncol. 2015;17(10):1386-92 - PMID: 26008604 - PMCID: PMC4578584 - DOI: 10.1093/neuonc/nov085
Hayano K, Tian F, Kambadakone AR, Yoon SS, Duda DG, Ganeshan B, Sahani DV
Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma.
J Comput Assist Tomogr. 2015;39(4):607-612 - PMID: 25793653 - PMCID: PMC4504795 - DOI: 10.1097/RCT.0000000000000239
Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK
Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma.
J Clin Oncol. 2015;33(10):1197-213 - PMID: 25713439 - PMCID: PMC4517055 - DOI: 10.1200/JCO.2014.55.9575
Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304 - DOI: 10.1073/pnas.1421632111
Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Proc Natl Acad Sci U S A. 2015;112(5):1547-52 - PMID: 25605928 - PMCID: PMC4321320 - DOI: 10.1073/pnas.1424024112
Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV
CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression.
AJR Am J Roentgenol. 2015;204(1):W11-8 - PMID: 25539263 - PMCID: PMC4479405 - DOI: 10.2214/AJR.13.12412
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG
Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Hepatology. 2014;59(4):1435-47 - PMID: 24242874 - PMCID: PMC3966948 - DOI: 10.1002/hep.26790
Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P
Translation of anticancer efficacy from nonclinical models to the clinic.
CPT Pharmacometrics Syst Pharmacol. 2014;3:e128 - PMID: 25098530 - PMCID: PMC4150926 - DOI: 10.1038/psp.2014.28
Richter C, Seco J, Hong TS, Duda DG, Bortfeld T
Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism.
Med Hypotheses. 2014;83(4):477-81 - PMID: 25175713 - DOI: 10.1016/j.mehy.2014.08.004
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation.
Neuro Oncol. 2014;16 Suppl 3:iii12 - PMID: 25165209 - PMCID: PMC4144509
Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK
Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.
J Natl Cancer Inst. 2014;106(8):ePub - PMID: 25082335 - DOI: 10.1093/jnci/dju187
Jain RK, Fukumura D, Duda DG
Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy.
In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (Editor: LM McManus & RN Mitchell). Elsevier Press, Oxford. 2014;:(in press)
Jain RK, Duda DG
Molecular Pathophysiology of Tumors.
In: Principles and Practice of Radiation Oncology, 6th Edition (Editors: E. C. Halperin, C. A. Parez, L. W. Brady), Lippincott, Williams & Wilkins, New York. 2014;Chapter 4:(in press)
Hato T, Goyal L, Greten TF, Duda DG, Zhu AX
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.
Hepatology. 2014;60(5):1776-82 - PMID: 24912948 - PMCID: PMC4211962 - DOI: 10.1002/hep.27246
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180 - DOI: 10.1016/j.ijrobp.2014.03.034
Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima SO, Popescu I
Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells.
Pancreas. 2014;43(5):795-800 - PMID: 24658318 - DOI: 10.1097/MPA.0000000000000106
Bucur O, Almasan A, Nikolajczyk BS, Nicolson GL, Lawler J, Velculescu VE, Draghici S, Leabu M, Avram D, Bucur I, Calautti E, Calin GA, Chauhan SC, Ciubotaru M, Constantinescu SN, Datta D, Duda DG, Friedman MT, Galardy PJ, Harris BT, Huarte M, Khalil AM, Marchetti D, Movileanu L, Nat R, Nucera C, Popa-Wagner A, Stancu AL, Zhu S, Liehn EA
Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry.
Discoveries (Craiova). 2013;1(1):e1 - PMID: 32309535 - PMCID: PMC6919543 - DOI: 10.15190/d.2013.1
Duda DG
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.
ISRN Cell Biol. 2013;2012:ePub - PMID: 24340224 - PMCID: PMC3856765 - DOI: 10.5402/2012/587259
Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 2013;45(12):1474-8 - PMID: 24185513 - DOI: 10.1038/ng.2806
Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK
Benefits of Vascular Normalization Are Dose and Time Dependent--Letter.
Cancer Res. 2013;73(23):7144-6 - PMID: 24265277 - PMCID: PMC3876035 - DOI: 10.1158/0008-5472.CAN-13-1989
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Proc Natl Acad Sci U S A. 2013;110(47):19059-64 - PMID: 24190997 - PMCID: PMC3839699 - DOI: 10.1073/pnas.1318022110
Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent F, Duda DG, Stuart K
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2 in Patients with Advanced Hepatocellular Cancer.
Clin Cancer Res. 2013;19(23):6614-23 - PMID: 24088738 - PMCID: PMC4795808 - DOI: 10.1158/1078-0432.CCR-13-1442
Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, Padera TP, Duda DG, Fukumura D, Jain RK
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
J Natl Cancer Inst. 2013;105(16):1188-1201 - PMID: 23899555 - PMCID: PMC3748004 - DOI: 10.1093/jnci/djt164
Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A, Buecker C, Schäfer R, Han X, Au P, Scadden DT, Duda DG, Fukumura D, Jain RK
Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
Proc Natl Acad Sci U S A. 2013;110(31):12774-9 - PMID: 23861493 - PMCID: PMC3732948 - DOI: 10.1073/pnas.1310675110
Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Neuro Oncol. 2013;15(8):1079-87 - PMID: 23828240 - PMCID: PMC3714160 - DOI: 10.1093/neuonc/not082
Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
J Hematol Oncol. 2013;6(1):51 - PMID: 23842041 - PMCID: PMC3722053 - DOI: 10.1186/1756-8722-6-51
Duda DG, Munn LL, Jain RK
Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?
J Natl Cancer Inst. 2013;105(11):762-5 - PMID: 23670727 - PMCID: PMC3672078 - DOI: 10.1093/jnci/djt114
Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
Cell. 2013;152(5):1065-76 - PMID: 23452854 - PMCID: PMC3587980 - DOI: 10.1016/j.cell.2013.01.036
Huang Y, Goel S, Duda DG, Fukumura D, Jain RK
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Cancer Res. 2013;73(10):2943-8 - PMID: 23440426 - PMCID: PMC3655127 - DOI: 10.1158/0008-5472.CAN-12-4354
Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, Jackson McCleary N, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG
Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423 - DOI: 10.1158/1078-0432.CCR-12-3041
Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Proc Natl Acad Sci U S A. 2012;109(43):17561-6 - PMID: 23045683 - PMCID: PMC3491458 - DOI: 10.1073/pnas.1215397109
Duda DG, Willett CG
Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Oncology (Williston Park). 2012;26(8):741-3 - PMID: 22957407 - PMCID: PMC3682651
Kozin SV, Duda DG, Munn LL, Jain RK
Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?
J Natl Cancer Inst. 2012;104(12):899-905 - PMID: 22572994 - PMCID: PMC3379722 - DOI: 10.1093/jnci/djs239
Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PLoS One. 2012;7(6):e38231 - PMID: 22701615 - PMCID: PMC3373492 - DOI: 10.1371/journal.pone.0038231
Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I
An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma.
Pancreas. 2012;41(7):1001-7 - PMID: 22722257 - DOI: 10.1097/MPA.0b013e3182546e13
Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170 - DOI: 10.1634/theoncologist.2011-0321
Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PLoS One. 2012;7(2):e26331 - PMID: 22347360 - PMCID: PMC3274514 - DOI: 10.1371/journal.pone.0026331
Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK
An isolated tumor perfusion model in mice.
Nat Protoc. 2012;7(4):749-55 - PMID: 22441293 - PMCID: PMC3375334 - DOI: 10.1038/nprot.2012.030
Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG
Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.
Nat Protoc. 2012;7(4):756-62 - PMID: 22441294 - PMCID: PMC3380105 - DOI: 10.1038/nprot.2012.031
Duyverman AM, Kohno M, Duda DG, Jain RK, Fukumura D
A transient parabiosis skin transplantation model in mice.
Nat Protoc. 2012;7(4):763-70 - PMID: 22441295 - PMCID: PMC3375333 - DOI: 10.1038/nprot.2012.032
Dawson MR, Chae SS, Jain RK, Duda DG
Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression.
Am J Cancer Res. 2011;1(2):144-54 - PMID: 21822499 - PMCID: PMC3150110
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK
Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010
Kozin SV, Duda DG, Munn LL, Jain RK
Is vasculogenesis crucial for the regrowth of irradiated tumours?
Nat Rev Cancer. 2011;11(7):532 - PMID: 21701514 - PMCID: PMC4790119 - DOI: 10.1038/nrc2007-c1
Zhu AX, Duda DG, Sahani DV, Jain RK
HCC and angiogenesis: possible targets and future directions.
Nat Rev Clin Oncol. 2011;8(5):292-301 - PMID: 21386818 - PMCID: PMC3266719 - DOI: 10.1038/nrclinonc.2011.30
Duda DG
Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer
Angiogenesis Foundation CME e-publication. 2011;:ePub
di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK
Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape.
Cancer Res. 2011;71(1):19-28 - PMID: 21199795 - PMCID: PMC3074948 - DOI: 10.1158/0008-5472.CAN-10-2602
Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Proc Natl Acad Sci U S A. 2011;108(9):3725-30 - PMID: 21321210 - PMCID: PMC3048115 - DOI: 10.1073/pnas.1100446108
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636
Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33 - PMID: 21833345 - PMCID: PMC3151740 - DOI: 10.1016/j.cloc.2011.04.003
Fukumura D, Duda DG, Munn LL, Jain RK
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
Microcirculation. 2010;17(3):206-25 - PMID: 20374484 - PMCID: PMC2859831 - DOI: 10.1111/j.1549-8719.2010.00029.x
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107
Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
Duda DG, Jain RK
Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010;28(17):2817-23 - PMID: 20458050 - PMCID: PMC2903316 - DOI: 10.1200/JCO.2009.26.3988
Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.
Cancer Res. 2010;70(14):5679-85 - PMID: 20631066 - PMCID: PMC2918387 - DOI: 10.1158/0008-5472.CAN-09-4446
Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT
The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients.
Nat Clin Pract Oncol. 2009;6:229-36
Perentes JY, Duda DG, Jain RK
Visualizing anti-tumor immune responses in vivo.
Dis Model Mech. 2009;2(3-4):107-10 - PMID: 19259379 - PMCID: PMC2650205 - DOI: 10.1242/dmm.001842
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Zhu AX, Duda DG, Sahani DV, Jain RK
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Cancer J. 2009;15(4):263-8 - PMID: 19672141 - PMCID: PMC4792519 - DOI: 10.1097/PPO.0b013e3181af5e35
Au P, Tam J, Duda DG, Lin PC, Munn LL, Fukumura D, Jain RK
Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo.
Am J Pathol. 2009;175(1):294-302 - PMID: 19477947 - PMCID: PMC2708815 - DOI: 10.2353/ajpath.2009.080887
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
J Clin Oncol. 2009;27(18):3027-35 - PMID: 19470923 - PMCID: PMC2702235 - DOI: 10.1200/JCO.2008.20.9908
Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Nat Rev Clin Oncol. 2009;6(4):229-36 - PMID: 19333229 - PMCID: PMC4793889 - DOI: 10.1038/nrclinonc.2009.14
Dawson MR, Duda DG, Fukumura D, Jain RK
VEGFR1-activity-independent metastasis formation.
Nature. 2009;461(7262):E4; discussion E5 - PMID: 19759568 - PMCID: PMC3065241 - DOI: 10.1038/nature08254
Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.
PLoS One. 2009;4(9):e6525 - PMID: 19763275 - PMCID: PMC2744279 - DOI: 10.1371/journal.pone.0006525
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099
Jain RK, Duda DG, Sorensen AG
Emerging paradigms and potential biomarkers of response and resistance in anatiangiogenic therapy of cancer
ASCO 2009 Educational Book. 2009;:716-21
Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
PLoS One. 2009;4(3):e4974 - PMID: 19333381 - PMCID: PMC2659427 - DOI: 10.1371/journal.pone.0004974
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356
Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
Jones R, Capen DE, Jacobson M, Cohen KS, Scadden DT, Duda DG
VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).
J Cell Mol Med. 2009;13(9B):3720-9 - PMID: 19426150 - PMCID: PMC2832073 - DOI: 10.1111/j.1582-4934.2009.00785.x
Willett CG, Duda DG, Xu L, diTomaso E, Boucher Y, Czito B, Ancukiewicz M, Clark J, Carroll M, Lauwers G, Jain RK
Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464
Jain RK, Duda DG, Batchelor TT, Sorensen AG, Willett CG
Normalization of tumor vasculature and microenvironment.
In: Angiogenesis: An Integrative Approach from Science to Medicine (Editors: W. D. Figg and J. Folkman), Springer. 2008;:173-282
Jain RK, Duda DG
Vascular and interstitial biology of tumors
In: Clinical Oncology. 4th Edition, (Editors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG), Elsevier, Philadelphia. 2008;:105-24
Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG
A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):388-97 - PMID: 18323810 - PMCID: PMC2676340 - DOI: 10.1038/nprot.2007.537
Jones RC, Capen D, Petersen B, Jain RK, Duda DG
A protocol for a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):378-87 - PMID: 18323809 - PMCID: PMC2676330 - DOI: 10.1038/nprot.2007.536
Huang P, Duda DG, Jain RK, Fukumura D
Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.
Comp Med. 2008;58(3):253-63 - PMID: 18589867 - PMCID: PMC2693079
Jain RK, Batchelor TT, Duda DG, Willett CG
Normalization of tumor vasculature and microenvironment.
In: Antiangiogenic Agents in Cancer Therapy. (Editors: Beverly Teicher and Lee Ellis), Humana Press. 2007;:261-76
Jain RK, Duda DG
Normalization of tumor vasculature and microenvironment by antiangiogenic therapy.
In: Angiogenesis: Mechanisms and Cancer Therapy (Editors: Dieter Marm and Norbert E. Fusenig), Springer-Verlag, Berlin. 2007;:577-92
Jain RK, Duda DG
Angiogenesis in Solid Tumors
In: Antiangiogenic Cancer Therapy (Editors: James L. Abbruzzese, Darren W. Davis and Roy S. Herbst), CRC Press, Boca Raton. 2007;:43-90
Willett CG, Duda DG, Jain RK
Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer.
Current Colorectal Cancer Reports. 2007;3:94-98
Duda DG, Cohen KS, Au P, Scadden DT, Willett CG, Jain RK
Detection of circulating endothelial cells: CD146- based magnetic separation enrichment or flow cytometric assay?
J Clin Oncol. 2007;25:e3-e5
Duda DG
Endothelial cell-based therapy for hematopoiesis
Blood. 2007;109(6):2272-3
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007;11(1):83-95 - PMID: 17222792 - PMCID: PMC2748664 - DOI: 10.1016/j.ccr.2006.11.021
Duda DG, Cohen KS, Scadden DT, Jain RK
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
Nat Protoc. 2007;2(4):805-10 - PMID: 17446880 - PMCID: PMC2686125 - DOI: 10.1038/nprot.2007.111
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175
Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT
Antiangiogenic agents for the treatment of glioblastoma.
Expert Opin Investig Drugs. 2007;16(12):1895-908 - PMID: 18041999 - DOI: 10.1517/13543784.16.12.1895
Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK
Targeted therapy in rectal cancer.
Oncology (Williston Park). 2007;21(9):1055-65; discussion 1065, 1070, 1075 passim - PMID: 17910311 - PMCID: PMC2686129
Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol. 2007;4(5):316-21 - PMID: 17464339 - PMCID: PMC2686127 - DOI: 10.1038/ncponc0813
Duda DG
American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996
Duda DG, Batchelor TT, Willett CG, Jain RK
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
Trends Mol Med. 2007;13(6):223-30 - PMID: 17462954 - PMCID: PMC2686126 - DOI: 10.1016/j.molmed.2007.04.001
Duda DG, Jain RK, Willett CG
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120 - DOI: 10.1200/JCO.2007.11.3985
Jain RK, Duda DG, Clark JW, Loeffler JS
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Nat Clin Pract Oncol. 2006;3(1):24-40 - PMID: 16407877 - DOI: 10.1038/ncponc0403
Duda DG
Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
Cancer Res. 2006;66(8):3967-70 - PMID: 16618712 - DOI: 10.1158/0008-5472.CAN-05-4536
Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH
Platelet-derived growth factor receptor-beta in Gorham's disease.
Nat Clin Pract Oncol. 2006;3(12):693-7 - PMID: 17139320 - PMCID: PMC2693369 - DOI: 10.1038/ncponc0660
Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.
Proc Natl Acad Sci U S A. 2006;103(4):855-60 - PMID: 16418262 - PMCID: PMC1348013 - DOI: 10.1073/pnas.0510412103
Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
J Clin Oncol. 2006;24(9):1449-53 - PMID: 16549839 - PMCID: PMC2718681 - DOI: 10.1200/JCO.2005.04.2861
Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Semin Oncol. 2006;33(5 Suppl 10):S35-40 - PMID: 17145523 - PMCID: PMC2686124 - DOI: 10.1053/j.seminoncol.2006.08.007
Jain RK, Au P, Tam J, Duda DG, Fukumura D
Engineering vascularized tissue.
Nat Biotechnol. 2005;23(7):821-3 - PMID: 16003365 - DOI: 10.1038/nbt0705-821
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
J Clin Oncol. 2005;23(31):8136-9 - PMID: 16258121 - DOI: 10.1200/JCO.2005.02.5635
Duda DG, Jain RK
Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow.
J Clin Invest. 2005;115(3):596-8 - PMID: 15765145 - PMCID: PMC1052004 - DOI: 10.1172/JCI24511
Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.
Nat Med. 2005;11(6):678-82 - PMID: 15880117 - PMCID: PMC2686110 - DOI: 10.1038/nm1247
Willett CG, Duda DG, Fischman A, Jain RK
Correspondence: PET concerns in bevacizumab treatment
Nature Medicine. 2004;10:561
Duda DG, Fukumura D, Jain RK
Role of eNOS in neovascularization: NO for endothelial progenitor cells.
Trends Mol Med. 2004;10(4):143-5 - PMID: 15162796 - DOI: 10.1016/j.molmed.2004.02.001
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med. 2004;10(2):145-7 - PMID: 14745444 - PMCID: PMC2693485 - DOI: 10.1038/nm988
Duda DG, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, Seed B, Jain RK
Differential transplantability of tumor-associated stromal cells.
Cancer Res. 2004;64(17):5920-4 - PMID: 15342367 - DOI: 10.1158/0008-5472.CAN-04-1268
Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Pancreas. 2004;28(3):311-6 - PMID: 15084978 - DOI: 10.1097/00006676-200404000-00019
Jain RK, Duda DG
Role of bone marrow-derived cells in tumor angiogenesis and treatment.
Cancer Cell. 2003;3(6):515-6 - PMID: 12842078 - DOI: 10.1016/s1535-6108(03)00138-7
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer.
Angiogenesis. 2003;6(1):15-24 - PMID: 14517400 - DOI: 10.1023/a:1025803600840
Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A
Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Oncogene. 2003;22(44):6857-64 - PMID: 14534532 - DOI: 10.1038/sj.onc.1206751
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA
Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S
Gene therapy for pancreatic cancer based on genetic characterization of the disease.
J Hepatobiliary Pancreat Surg. 2002;9(1):32-8 - PMID: 12021895 - DOI: 10.1007/s005340200002
Lefter LP, Furukawa T, Sunamura M, Duda DG, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A
Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines.
Genes Chromosomes Cancer. 2002;34(2):234-42 - PMID: 11979557 - DOI: 10.1002/gcc.10060
Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S
Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Pancreas. 2002;25(2):111-21 - PMID: 12142732 - DOI: 10.1097/00006676-200208000-00001
Ding L, Sunamura M, Kodama T, Yamauchi J, Duda DG, Shimamura H, Shibuya K, Takeda K, Matsuno S
In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells
Br J Cancer. 2001;85:431-8 - PMID: 11487277 - PMCID: PMC2364062 - DOI: 10.1054/bjoc.2001.1911
Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S
The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice.
Pancreas. 2000;20(3):227-33 - PMID: 10766447 - DOI: 10.1097/00006676-200004000-00002
Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Cancer Res. 2000;60(4):1111-6 - PMID: 10706132
Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H
Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus.
Hum Gene Ther. 2000;11(2):223-35 - PMID: 10680837 - DOI: 10.1089/10430340050015978
240